TRuC Construct Assembly & T Cell Engineering Service

Online Inquiry

Background Service What We Can Offer Workflow Highlights FAQs Contact

Creative Biolabs provides a TRuC Construct Assembly & T Cell Engineering Service to address key challenges in conventional CAR-T programs, including antigen escape, tumor recurrence, and excessive cytokine release. This service enables the development of safer and more potent immunotherapies with improved tumor control and enhanced cellular persistence. Through a proprietary engineering platform, antibody-based binding domains are precisely integrated into the intact T cell receptor (TCR) complex, allowing therapeutic cells to leverage physiological TCR signaling pathways and outperform conventional synthetic receptor designs in both safety and functional durability.

Introduction

T cell receptor fusion construct (TRuC) T cell technology represents a revolutionary shift toward physiological immune reprogramming. By fusing binders to subunits, TRuCs become a functional component of the intact TCR complex, utilizing all ten ITAMs for signaling. TRuC-T cells mediate potent anti-tumor responses with significantly lower cytokine release than CAR-T cells, even in co-stimulatory ligand-deficient environments. This makes the platform an ideal solution for both hematological malignancies and challenging solid tumors.

Service

Creative Biolabs provides an end-to-end solution for the design, assembly, and validation of TRuCs. Our service is specifically designed to bypass the limitations of second-generation CARs by utilizing the entire signaling machinery of the TCR complex. We offer precise engineering to ensure your therapeutic candidate achieves optimal stoichiometry and physiological activation.

What you receive:

Optimized TRuC construct panels across multiple TCR/CD3 subunits and linker configurations.
Validated engineered primary T cells with stable receptor expression.
Head-to-head functional data enabling rapid construct down-selection.

Problems we solve:

Low surface expression and poor receptor assembly.
Suboptimal activation or background signaling.
Unclear structure-function relationships among different fusion designs.

Discover How We Can Help - Request a Consultation.

What We Can Offer

Multi-subunit fusion engineering platforms	Linker and spatial configuration optimization
Parallel fusion of targeting binders to different TCR and CD3 subunits. Independent design of extracellular, transmembrane, and intracellular junction regions.	Length- and flexibility-tunable peptide linkers. Steric accessibility and folding compatibility screening.
Expression and integration analytics	Functional screening platforms
Flow cytometry-based surface expression profiling. TCR/CD3 co-assembly and stability assessment.	Antigen-dependent activation assays. Cytokine secretion and cytotoxicity profiling. Background activation and tonic signaling assessment.

Our Workflow

Workflow of TRuC Construct Assembly & T Cell Engineering. (Creative Biolabs Original)

The final deliverables include a comprehensive technical report detailing construct assembly, transduction efficiency, and expansion kinetics; raw data from functional assays, including cytotoxicity curves and multiplex cytokine quantification; and validated engineered T cell aliquots for downstream preclinical evaluation.

Core Benefits

Customized Binder Integration: High-affinity scFv domains are fused to any of the five TCR subunits to reprogram the complete TCR complex.
Bispecific & Multi-specific Engineering: Development of dual-targeting TRuC constructs to mitigate clonal growth and tumor antigen escape.
Advanced Cytokine Co-expression: Customized engineering of TRuC-T cells to secrete immuno-modulatory factors, enhancing T cell proliferation, survival, and chemotaxis.
Precision Signaling Optimization: Systematic pairing of TCR/CD3 subunits to ensure stable receptor integration and maximize myeloma-specific cytotoxicity.

FAQs

Q1: What is the main advantage of TRuC over traditional CAR-T?

A1: TRuCs engage the entire TCR complex, providing more sensitive, physiological signaling and lower cytokine production, which can lead to better safety profiles and higher sensitivity to low-antigen-density cells.

Q2: Which TCR subunit is best for fusion?

A2: While we can fuse to several subunits, the CD3 epsilon subunit often shows high expression and stability because each TCR complex naturally contains two CD3 epsilon molecules.

Q3: Can I engineer bispecific TRuC-T cells to prevent antigen escape?

A3: Yes. We specialize in bispecific constructs to target multiple antigens simultaneously, significantly reducing the likelihood of tumor relapse due to antigen loss.

Q4: Are TRuC-T cells effective against solid tumors?

A4: Absolutely. TRuC-T cells have demonstrated robust efficacy in solid tumor models like glioblastoma by providing superior tumor penetration and less exhaustion in the suppressive microenvironment.

Partner with Us

Creative Biolabs offers a world-class platform for TRuC Construct Assembly & T Cell Engineering, providing researchers with the tools to build more sensitive, safer, and more persistent adoptive cell therapies. Whether you are targeting relapsed multiple myeloma or refractory solid tumors, our expertise in TCR complex mechanics ensures your project is grounded in cutting-edge science. Our platform ensures lower cytokine release, reducing the risk of Cytokine Release Syndrome (CRS) while maintaining potent anti-tumor activity. For detailed project discussions and a personalized quote, please contact us.

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.